Genmab — Oktober 2020
-
-
På baggrund af dagens dara tal hæver Jefferies "bunden" på den negative effekt patentslagsmål mellem JnJ og Genmab, vil have på Genmab' værdiansættelse. Nu "blot" - 15 % mod tidligere - 25 %, såfremt sagen ikke falder ud til Genmabs fordel
-
-
Sry for at bypasse nyhederne her på PI. Opfordrer alle til at om udforske PI og alle de nye feeds der implementeres her. On-place-to-go supermarked
-
Tak LLI..Jeg laver snart en introduktionsvideo.
-
mht. retssagen - Mon ikke Genmab selv skal have indgået en aftale om betaling af royaltyes, hvis der skal gælde sådan en... Ellers er det vel stadig afregning for det aktive komponent Genmab levere i en hvilken som helst drug... Jeg tror på ledelsen har styr på det, ellers bliver jeg MEGET skuffet med den hyre de får, alt inklusiv.
-
God onsdag morgen. I modsætning til en sag der indankes for en domstol af en part, er begge parter i voldgiftsager enige om, af få afprøvet et tvivlsspørgsmål ved en uvildig instans. En klar fordel er, at parterne kan udpege en voldgiftdommer med specifik viden, på netop det område hvor tvivlen er opstået, hvor dommerne i en retssag ved domstolene er generalister. Hvis der ikke er en klokkeklar vinder i sagen, kan voldgiftdommeren også medvirke til forlig mellem parterne.
-
God morgen. :_)
-
Johnson & Johnson (JNJ) Management on Q3 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4378919-johnson-johnson-jnj-management-on-q3-2020-results-earnings-call-transcript?part=single
-
-Maybe I can take the question on the EGFR-cMet antibody amivantamab. It is a really exciting project for us. You asked about near-term and long-term. First on the antibody itself, it's a really interesting antibody. It's unique to us and it incorporates both EGFR binding peak and the CMS binding peak and CMS is common resistance mechanism for EGFR therapy. So it's both the primary mutation and the resistance mechanism at the same time.
-
The near-term plan is to go forward with an Exon 20 EGFR tumor, non-small cell lung cancer, there are really no good opportunities for patients with Exon 20 signatures. But that's how we will begin but our eyes are on the larger EGFR mutation market and patients in non-small lung cancer. So with time, we plan on exploring multiple lines of therapy and eventually all EGFR containing tumors."
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind